• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xoma Royalty Corporation (NQ: XOMA )

    31.10 +0.24 (+0.78%)
    Streaming Delayed Price Updated: 3:39 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Xoma Royalty Corporation

    < Previous 1 2 Next >
    XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
    From XOMA Corporation
    Via GlobeNewswire
    Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty to Present at Upcoming Investor Conferences in September
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Corporation Announces Closing of Tender Offer
    Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right 
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
    Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at Upcoming Investor Conferences in March
    From XOMA Corporation
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
    Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
    From XOMA Corporation
    Via GlobeNewswire
    FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
    FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Stock Repurchase Program of up to $50 Million
    Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024 
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.